Ashutosh Sureka

CVS slides over 3% as bearish momentum persists amid split plans and regulatory concerns

CVS slides over 3% as bearish momentum persists amid split plans and regulatory concerns
CVS Health slides 3.40% today

CVS Health Corp (CVS) fell 3.4% after the company's plan to split into two independent publicly traded entities weighed on investor sentiment. The move is supported by pronounced technical weakness, with the stock remaining below major moving averages and immediate resistance levels.

CVS price prediction
24H 0.1%
$81.43
48H 0.12%
$81.45
7D -1.98%
$79.74
1M -6.93%
$75.71
3M -4.92%
$77.35
6M -13.99%
$69.97
12M 1.08%
$82.23
Current price: $81.35 -4.4600 5.20%
Closed 11/18
Daily range 81.10 Arrow from to Icon 85.76
Weekly range 81.09 Arrow from to Icon 90.64
Loading...

Highlights

  • CVS Health confirmed it will split into two publicly traded companies and restart share repurchases next quarter.
  • A proposed CMS rule could impose stricter Medicare Advantage audits and impact the Aetna insurance segment.
  • Shares of CVS Health trade below major moving averages with strong bearish momentum and a projected range of $79.87 to $85.91 over five days.

Ongoing selling as split news and regulatory risks strain sentiment

CVS Health recently announced plans to split into two independent publicly traded companies, a move that followed its November 4 disclosure and contributed to ongoing selling in the shares. Investor sentiment was further affected by a proposed CMS rule for stricter Medicare Advantage audits, which could impact the Aetna insurance business. CVS has also maintained its dividend at the same level for 12 consecutive quarters while prioritizing share buybacks and the upcoming corporate split. Plans to restart repurchases in the next quarter were confirmed, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees deep-seated issues weighing on CVS. He notes persistent price weakness, with the stock trading below all key moving averages and meeting heavy resistance at $84.67. The corporate split has failed to inspire confidence and exposes the company to execution risk. Technical indicators remain mostly bearish, with momentum clearly to the downside and high volatility. He warns, "Unless CVS breaks above $85.91, further declines are the likeliest scenario and any attempts to rebound remain unconvincing in the current setup."
Viktoras Karapetjanc, expert at Traders Union, considers the split a bold strategic step with long-term benefits. He argues that ongoing share buybacks and a steady dividend create a solid base for renewed investor interest. While current pressure remains, he expects the market to eventually reward CVS's forward-looking transformation. Karapetjanc affirms, "Once regulatory uncertainty eases and the market digests the split, CVS will regain upward momentum and offer attractive growth opportunities."
Sholanke Dele, market strategist, emphasizes the negative sentiment dominating CVS after the recent corporate announcements. He points out that stricter Medicare Advantage audits and broad selling pressure erode support levels fast. The rapid decline to session lows shows a lack of buyer conviction. Dele states, "Investors should be wary — sustained selling and increased volatility signal more downside risk in the near term."
CVS Health Corp asset chart
CVS Health Corp price dynamics. Source: TradingView.

Broad momentum loss confirmed by bearish signals and weak support

CVS is trading below the 20-, 50-, and 200-day moving averages ($88.90, $89.29, and $89.29), highlighting persistent downward momentum across all timeframes. The nearest resistance is at $84.67, with immediate support at $82.67. Momentum remains firmly bearish, as signaled by a strong sell from MACD and weak trend strength on the ADX. Oscillators like RSI, Stochastic RSI, and CCI are neutral, indicating a lack of overbought or oversold conditions. Bearish pressure is dominant intraday, with negative BBP and the stock trading near session lows. Volatility is elevated at 3.71%, reinforcing the downside bias.

Previously it was reported that CVS Health was contending with technical resistance and sustained selling pressure despite long-term initiatives in innovation and healthcare delivery. The current article strengthens that assessment, as heightened volatility and negative momentum reinforce the importance of monitoring $79.87 as a key support level for potential further downside risk.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.